AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Vitamin D3 receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P11473

UPID:

VDR_HUMAN

Alternative names:

1,25-dihydroxyvitamin D3 receptor; Nuclear receptor subfamily 1 group I member 1

Alternative UPACC:

P11473; B2R5Q1; G3V1V9; Q5PSV3

Background:

The Vitamin D3 receptor, also known as the 1,25-dihydroxyvitamin D3 receptor or Nuclear receptor subfamily 1 group I member 1, is a pivotal nuclear receptor that mediates the effects of vitamin D3. It functions by binding to vitamin D3, entering the nucleus, and forming heterodimers with the retinoid X receptor. These complexes then bind to DNA, activating the transcription of genes involved in calcium homeostasis and response to vitamin D3.

Therapeutic significance:

The Vitamin D3 receptor plays a crucial role in Rickets vitamin D-dependent 2A, a disorder characterized by severe rickets, hypocalcemia, and secondary hyperparathyroidism, often accompanied by total alopecia. Understanding the role of the Vitamin D3 receptor could open doors to potential therapeutic strategies for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.